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Alveolar macrophages (AMF) are the proto­
typical MFs of the lung that have important 
functions in lung development, surfactant ho­
meostasis, pathogen clearance, and immune 
homeostasis (Lambrecht, 2006). Among tissue 
resident MFs, AMFs have a peculiar phenotype 
in that they are highly autofluorescent, express 
low levels of the phagocytic receptor CD11b, 
yet high levels of the integrin CD11c, and high 
levels of the lectin SiglecF, allowing them to 
be easily recognized among other myeloid cells 
of the lung (Gautier et al., 2012b; Misharin et al., 
2013). For a long time, AMFs were considered 
the prototypical cells belonging to the unified 
mononuclear phagocyte system (MPS), a family 
of tissue­resident MFs proposed to derive from 
circulating BM­derived monocytes that seed the 
various tissues in the steady state and continu­
ously differentiate locally into tissue­resident MFs 
(van Furth and Cohn, 1968; Geissmann et al., 
2010). The MPS concept with the circulating 
monocyte as the central precursor to all tissue 
MFs was based on in vivo adult monocyte 
transfer experiments (Geissmann et al., 2003), 
in vivo thymidine­(3)H labeling experiments 
(van Furth and Cohn, 1968), and the study of 
irradiation chimeras (Virolainen, 1968). Deple­
tion of AMFs using intratracheal administration 
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Tissue-resident macrophages can develop from circulating adult monocytes or from primitive 
yolk sac–derived macrophages. The precise ontogeny of alveolar macrophages (AMFs) is 
unknown. By performing BrdU labeling and parabiosis experiments in adult mice, we found 
that circulating monocytes contributed minimally to the steady-state AMF pool. Mature 
AMFs were undetectable before birth and only fully colonized the alveolar space by 3 d after 
birth. Before birth, F4/80hiCDblo primitive macrophages and Ly6ChiCDbhi fetal monocytes 
sequentially colonized the developing lung around E2.5 and E6.5, respectively. The first 
signs of AMF differentiation appeared around the saccular stage of lung development 
(E8.5). Adoptive transfer identified fetal monocytes, and not primitive macrophages, as the 
main precursors of AMFs. Fetal monocytes transferred to the lung of neonatal mice acquired 
an AMF phenotype via defined developmental stages over the course of one week, and 
persisted for at least three months. Early AMF commitment from fetal monocytes was 
absent in GM-CSF–deficient mice, whereas short-term perinatal intrapulmonary GM-CSF 
therapy rescued AMF development for weeks, although the resulting AMFs displayed an 
immature phenotype. This demonstrates that tissue-resident macrophages can also develop 
from fetal monocytes that adopt a stable phenotype shortly after birth in response to  
instructive cytokines, and then self-maintain throughout life.
© 2013 Guilliams et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Figure . AMFs self-maintain locally with minimal contribution from circulating hematopoietic precursors. BAL (A) and total lung (B) were 
harvested from adult mice and stained for CD11b, F4/80, SiglecF, CD64, Ly-6C, and MHCII and evaluated for autofluorescence, FSC, and SSC profile  
(C). (D) CD45.1+CD45.2+ mice were lethally irradiated and reconstituted with equal amounts of CD45.1+ WT and CD45.2+CCR2/ BM cells. Radio-resistant cells, 
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tissue­resident MFs, we readdressed the origin of AMFs and 
found that these cells are not replenished continuously from 
adult monocytes, but instead derive from fetal monocytes that 
seed the lung before birth and develop into long­lived CD11chi, 
SiglecFhi AMFs shortly after birth in response to an instructive 
signal provided by granulocyte­MF colony­stimulating factor 
(GM­CSF). In GM­CSF–deficient mice, a few days of peri­
natal cytokine therapy were able to restore AMF development 
for weeks. Differentiation of AMFs from fetal monocytes starts 
around the time alveoli develop (E18.5), and is completed over 
the course of 1 wk. These findings reconcile previous contro­
versies on AMF ontology and provide new clues to the devel­
opmental origin of this unique MF population resident in the 
lung compartment from fetal monocytes.
RESULTS
Identification of lung mononuclear cells
We first addressed if AMFs derived from a circulating precur­
sor population. To precisely define the different mononuclear 
cells of the lung, we performed 10­color flow cytometry on 
bronchoalveolar lavage (BAL) fluid and total lung cell suspen­
sions after blood was rinsed from the pulmonary circulation. 
First, neutrophils (Ly­6GhiCD11bhiCD64loLy­6Chicells), eosin­
ophils (SiglecFhiCD11bhiCD64loLy­6Cint cells), T cells (CD3hi 
CD11bloCD64lo cells), and B cells (CD19hiCD11bloCD64lo cells) 
were outgated (unpublished data). Second, not to miss any 
mononuclear cells, we first gated lung cells on a broad mono­
nuclear gate consisting of F4/80+ and CD11b+ cells. AMFs 
have a distinct phenotype among tissue­resident MFs and can 
be unequivocally identified within the F4/80+CD11b+ gate 
as SiglecFhiCD11chi cells in the BAL fluid (Fig. 1 A; Gautier 
et al., 2012b). The same population could also be found in 
total cell suspensions of lung tissue (Fig. 1 B), when BAL 
fluid was not collected before homogenization. In lung tis­
sue, the F4/80+CD11b+ gate contained a second population 
of CD11bhiF4/80int cells that were further subdivided into 
CD11cloSiglecFlo cells and CD11cintSiglecFlo cells. Using this 
gating strategy, SiglecFhiCD11chi cells were large (FSChi), and 
granular (SSChi) highly autofluorescent cells (Fig. 1 C), typi­
cal of alveolar MFs (Vermaelen and Pauwels, 2004). We next 
measured the expression of various markers on these three 
identified populations of lung cells (Fig. 1 C). The universal 
MF marker CD64 was expressed highly on SiglecFhi CD11chi 
AMFs, but not on the other two populations. The marker 
Ly­6C is highly expressed on circulating monocytes, but less on 
monocytes that patrol the blood vessels (Geissmann et al., 2003). 
The CD11bhiF4/80intCD11cloSiglecFlo population expressed 
of diphtheria toxin (DT) to CD11c­DT receptor (DTR) mice 
followed by transfer of monocytes demonstrated that adult 
BM­derived monocytes can indeed differentiate into AMFs 
in vivo (Landsman and Jung, 2007). However, genetic fate map­
ping experiments using hematopoietic (Myb) or monocyte­
based (Cx3cr1) fate mapping gene promoters found these cells 
to be only partially (Schulz et al., 2012) or not at all (Yona et al., 
2013) of adult hematopoietic or monocytic origin, which was 
hard to reconcile with the MPS concept. Part of the confu­
sion on the precise origin of AMFs also stems from the fact 
that these cells are long lived and relatively radioresistant de­
pending of the radiation dose, complicating the interpretation 
of radiation chimeric experiments. Therefore, whereas some 
proposed a monocytic origin for AMF (Godleski and Brain, 
1972; van oud Alblas and van Furth, 1979; Kennedy and 
Abkowitz, 1997; Kennedy and Abkowitz, 1998) others pro­
posed that AMFs would be mainly long­lived, self­renewing 
cells (Tarling et al., 1987; Murphy et al., 2008).
The MPS paradigm with the circulating monocyte as the 
central replenisher of all tissue MFs has also been challenged 
recently by the observation that MFs appear in embryonic 
tissues before the development of monocytes, making it hard 
to envisage a precursor­product relationship for monocytes 
and MFs (Takahashi et al., 1989; Ginhoux et al., 2010; Hoeffel 
et al., 2012; Schulz et al., 2012). Supporting the idea of primi­
tive MF progenitors seeding the tissues, some tissue­resident 
MFs like microglia (Ajami et al., 2007, 2011) and Kupffer cells 
(Bouwens et al., 1986a,b; Yamamoto et al., 1996) were found 
not to derive from circulating hematopoietic precursors but 
to be long­lived, self­renewing cells. Using genetic fate map­
ping, microglia was found to be derived from fetal yolk sac 
MFs that seed the brain before birth and then maintain locally 
without any input from adult hematopoietic precursors or 
circulating monocytes (Ginhoux et al., 2010). When first pro­
posed, the primitive origin of microglia was thought to rep­
resent an exception to the MPS concept, as microglia populate 
a cellular niche that is normally not accessible to hematopoi­
etic precursors because of the blood–brain barrier that closes 
shortly before birth. However, subsequent studies found that 
most tissue­resident MFs, including Kupffer cells, splenic MFs, 
peritoneal MFs, and kidney MFs, are not of adult hemato­
poietic origin in the steady state (Schulz et al., 2012; Yona 
et al., 2013), leading to the generalization that these cells 
may also develop directly from yolk sac–derived fetal MFs 
(Gomez Perdiguero et al., 2013).
Given the controversies surrounding the development of 
AMFs and these recent developments on the origin of other 
distinguished as CD45.1+CD45.2+ cells, were gated out, and the remaining BM-derived cells of the indicated populations were analyzed for their ratio of 
CD45.1+ WT and CD45.2+CCR2/ cells. (E) Summary data from five independent chimeric mice. (F) Parabiotic mice were generated by suturing together 
CD45.1+ WT and CD45.2+CCR2/ mice. The percentage of cells of CD45.1+ WT donor origin was determined in B cells, neutrophils, and monocytes in the 
blood and AMFs in the lungs of the CD45.2+CCR2/ parabionts. (G) Adult C57BL/6 mice received BrdU continuously for 28 d. Mice were sacrificed at 
regular intervals, and incorporation of BrdU in lung AMFs and monocytes was evaluated. (H) Adult C57BL/6 mice were sacrificed and Ki-67 expression 
(left) was determined in AMFs. The isotype staining is shown (right). Data represent at least three (A– E) or two (F– H) independent experiments involving 
at least six (E) and four (F and G) independent mice.
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monocyte egress from the BM in the CD45.2+ Ccr2/ mice, 
donor CD45.1+ WT monocyte constituted 80% of the mono­
cytes in these mice. However, in our experiments AMFs 
achieved a much lower chimerism in parabionts with <5% of 
AMFs originating from the parabiotic partner. This indicates 
that circulating adult hematopoietic precursors only minimally 
participate to the AMF pool. These data are congruent with a 
recent report from the Merad group (Hashimoto et al., 2013).
We next sought to find evidence for the lack of monocyte 
contribution to the AMF pool in unmanipulated mice. We 
reasoned that if monocytes were precursors to AMFs, then 
studying BrdU incorporation kinetics should allow us to study 
progenitor–product relationships (Kamath et al., 2002). We 
exposed C57BL/6 mice continuously to BrdU in the drink­
ing water for 4 wk after an initial i.p. injection of BrdU. As 
shown in Fig. 1 G, whereas almost all monocytes were rapidly 
BrdU labeled within 2 d, AMFs slowly accumulated 30% of 
BrdU incorporation after 4 wk of continuous BrdU exposure. 
The slow accumulation of BrdU could come from BrdU+ 
circulating hematopoietic progenitors or from local prolifera­
tion of AMFs. We therefore evaluated the expression of the 
cell cycle protein Ki­67, which labels dividing and recently 
divided daughter cells. As shown in Fig. 1 H, a small popula­
tion (<5%) of Ki­67+ dividing cells could be found among 
AMFs, suggesting a slow local proliferation of AMFs.
To further evaluate whether circulating monocytes con­
tribute to the AMF pool of unmanipulated mice, we trans­
ferred 2 × 106 CD45.1+ Ly­6Chi CD11bhi monocytes into 
adult Ccr2/ CD45.2+ mice, but we could not recover any 
transferred monocyte developing into SiglecFhiCD11chi AMFs 
7 d after the transfer, although we readily recovered trans­
ferred monocytes as mature intestinal MFs 7 d after transfer 
(not depicted; Tamoutounour et al., 2012; Bain et al., 2013).
Alveolar MFs appear in the alveolar space  
during the first week of life
Microglia and Langerhans cells (LCs) derive from embryonic 
precursors that seed the brain and the skin before birth and 
maintain themselves locally throughout life (Chorro et al., 
2009; Ginhoux et al., 2010; Hoeffel et al., 2012). As AMFs also 
did not derive from circulating monocytes and showed signs 
of low­grade proliferation, we next addressed the ontogeny of 
AMF before and after birth. Little is known about the ontog­
eny of the lung immune system in relation to lung development, 
which proceeds via a pseudoglandular stage (E9.5–E16.5), a 
canalicular stage (E16.5–17.5), and a saccular stage (E18.5 to 
postnatal day [PND] 5). During the latter stage, canaliculi de­
velop numerous sacs that are the precursors to the alveoli. As 
shown in Fig. 2 A, we first measured the kinetics of CD45+ 
leukocyte accumulation in the lung. The percentage of CD45+ 
cells started expanding around E18, coinciding with the start 
of the saccular stage (Fig. 2 C). We next addressed the ontog­
eny of mononuclear cells (Fig. 2 B). At day E12, the major 
population of mononuclear cells in the CD11b+ F4/80+ gate 
consisted of F4/80hi CD11bint cells, which had an intensity of 
staining resembling adult mature AMFs. However, these cells 
high levels of Ly­6C, identifying these cells as monocytes. In 
support, they also did not express the MF marker CD64 and 
were SSClo and FSClo. The CD11bhiF4/80intCD11cintSiglecFlo 
population was a mixed population in which some cells ex­
pressed low levels of Ly­6C (likely representing residual ves­
sel patrolling monocytes) and 20% expressed high levels of 
MHCII (thus representing mature CD11b+ cDCs). Interstitial 
MFs (defined as CD11bhi, F4/80hi, CD11c, SiglecFlo, MHCII+, 
CD64+ cells represented <5% of cells in the CD11b+ F4/80+ 
mononuclear gate and <0.2% of lung suspension cells (dot 
plots not depicted).
Adult circulating monocytes contribute to the AMF pool  
in irradiated mice, but not in homeostasis
Previous work supporting the fact that AMFs belong to the 
MPS system have studied AMF pool replenishment after 
whole­body irradiation, illustrating that the AMF pool can 
derive from an adult hematopoietic progenitor. However, it 
has not been formally shown that circulating monocytes con­
stitute the main precursor of the AMF pool after irradiation, 
or only participate minimally to the AMF pool. To test this, 
congenic mice coexpressing CD45.1 and CD45.2 were le­
thally irradiated and reconstituted with a 1:1 mixture of BM 
cells isolated from CD45.1+ C57BL/6 WT mice and from 
CD45.2+ Ccr2/ mice. These B6 (CD45.1) WT + B6 
(CD45.2) Ccr2/ → B6 (CD45.1–CD45.2) competitive 
chimeras were analyzed 8 wk after BM transfer. As CCR2 is 
critical for egress of monocytes from the BM (Serbina and 
Pamer, 2006), competitive chimerism allowed us to address 
the relative contribution of circulating monocytes to AMF 
replenishment after whole body irradiation. As expected, 
Ly­6Chi blood monocytes were primarily composed of 
CD45.1+CCR2+ donor cells, whereas neutrophils and B cells 
were comprised of almost equal percentages of CD45.1+ and 
CD45.2+ donor cells (Fig. 1 D, group summarized in Fig. 1 E). 
8 wk after reconstitution, AMFs still contained between 5 and 
10% of host­derived, radio­resistant CD45.1+CD45.2+ cells, 
illustrating the relative radioresistance of these cells (Fig. 1 E). 
The donor­derived AMFs showed CD45 chimerism identical 
to those of Ly­6Chi blood monocytes, demonstrating that upon 
severe depletion, AMFs derive from circulating monocytes.
We next questioned whether circulating monocytes par­
ticipate to the AMF pool in the adult life when AMFs are 
not experimentally depleted by irradiation. We therefore per­
formed parabiosis experiments between CD45.1+ WT mice 
and CD45.2+ Ccr2/ mice. After 8 wk of parabiosis, we ana­
lyzed the contribution of CD45.1+ WT cells within the CD45.2+ 
Ccr2/ mice. There was an almost even distribution of long­
lived recirculating cells, and donor CD45.1+ WT B lympho­
cytes represented 40% of circulating blood B lymphocytes of 
the parabiont CD45.2+ Ccr2/ partner (Fig. 1 F). However, 
short­lived circulating cells like neutrophils exchanged 20% 
of the cells among the parabiont partner. Such uneven distribu­
tion between parabionts likely results from the fact that neutro­
phils do not spend enough time in the circulation to equilibrate 
between the parabionts (Liu et al., 2007). Due to a defect in 
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Figure 2. Alveolar MFs appear in the alveolar space during the first week of life. Lungs were harvested at various time points before and after 
(PND) the DOB. (A and C) Flow cytometry staining for CD45+ cells. (B) CD11b+F4/80+ myeloid cells were gated and analyzed for CD11c and SiglecF expres-
sion. (D) Paraffin lung sections stained with hematoxylin. (E) Cryosection of lungs stained with DAPI (blue) and SiglecF (red). Data in A–E represent at least 
two independent experiments involving at least three independent mice per time point.
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SiglecFloCD11clo cells still contained some Ly­6CloF4/80hi 
fetal MFs, but Ly­6ChiF4/80int fetal monocytes were the pre­
dominant population. Within the SiglecFloCD11clo cells, some 
monocytes had already lost Ly­6C, a common feature of mono­
cytes differentiating into mature MFs or DCs (Tamoutounour 
et al., 2012; Plantinga et al., 2013). Between PND1 and PND3, 
SiglecFhiCD11chi cells appeared very suddenly, and these were 
Ly­6CloF4/80hi cells, like adult AMFs. The SiglecFloCD11cint 
cells contained more MHCII DCs (not depicted), but still con­
tained many mononuclear cells that were losing Ly­6C. At 
PND3 (Fig. 3, A–C, third column), the SiglecFloCD11clo frac­
tion hardly contained any F4/80hi fetal MFs anymore. At 
PND14 (Fig. 3, A–C, fourth column), the ensemble of lung 
mononuclear cell types resembled the adult state, and the 
CD11cint population had lower mean fluorescence expression 
of SiglecF. In Fig. 3 E, the relative distribution of all these cell 
populations is plotted against time. The appearance of mature 
AMFs at PND3 was preceded by a surge in SiglecFloCD11cint 
CD64int cells that looked like immature AMFs on SEM. We 
will therefore call this population preAMFs.
Fetal monocytes give rise to self-maintaining AMFs  
through a preAMF intermediate step
To verify whether fetal monocytes or fetal MFs are the direct 
precursors to AMFs, we designed a competitive transfer ex­
periment (Fig. 4). CD45.1 fetal MFs and CD45.2 monocytes 
were isolated from E17 lungs and transferred together in a 1:1 
ratio i.n.) into CD45.1+ CD45.2+ mice on their DOB, i.e., 
when the AMF niche is still empty. 7 d after transfer, the fate 
of the donor cells was evaluated. Whereas at day 7, most of 
the AMFs were of host CD45.1+CD45.2+ phenotype in these 
nonirradiated mice (Fig. 4 A), the fate of donor cells could 
clearly be defined. As shown in Fig. 4 (A and B), transferred 
AMFs were significantly more derived from fetal monocyte–
derived MFs than from fetal MFs. Similar results were found 
when the congenic donor pair was switched over (i.e. when 
fetal monocytes were CD45.1 and fetal MFs were CD45.2) 
or when the recipient mice were analyzed at 6 weeks after 
transfer (unpublished data) instead of 7 days after transfer 
(Fig. 4, A and B). A similar setup also allowed us to follow the 
differentiation of developing AMFs from adoptively transferred 
fetal monocytes. Therefore, we i.n. transferred fetal CD45.1+ 
monocytes into CD45.2+ mice on DOB and checked the 
phenotypic changes of the cells in the following days and 
weeks. Strikingly, transferred CD45.1 cells could be found up 
to 11 wk after transfer (Fig. 4 C). Fetal monocytes gradually 
increased expression of CD11c, SiglecF, F4/80, and CD64 lev­
els, while down­regulating first Ly­6C and then CD11b, going 
through a Ly­6CintCD11bhiF4/80intLy­6CintCD64int interme­
diate stage, essentially validating these cells as preAMFs. The 
kinetic of the differentiation of the transferred monocytes fits 
a developmental scheme that would go from fetal monocytes 
over preAMFs to mature AMFs within 6 to 7 d, which was also 
seen in Fig. 3 E. We could still trace back AMF originating from 
transferred monocytes 3 mo after transfer. Moreover, within 
one transfer experiment, the percentage of donor­derived 
were completely negative for SiglecF and CD11c. They were 
most reminiscent of the phenotype of primitive MFs that arise 
at E9 and E12 from the yolk sac, and are also CD11bint F4/80hi 
(unpublished data). Progressively, the mononuclear gate be­
came replete with a second F4/80int CD11bhi population, and 
there was a gradual increase in the cells expressing intermedi­
ate levels of CD11c. However, before birth, the mononuclear 
gate was completely devoid of SiglecFhiCD11chi AMFs. Around 
the date of birth (DOB), the mononuclear gate was in transi­
tion, and it was no longer possible to clearly discern F4/80hi 
from F4/80int cells. There was a marked increase in CD11cint 
cells. Mature SiglecFhiCD11chi AMFs only appeared between 
PND1 and PND3, when a predominant population of F4/80hi 
cells was again apparent in the mononuclear gate. Interestingly, 
this time point coincided with the first appearance of large 
mononuclear cells in the alveolar space (Fig. 2 D). Mature 
SiglecF­expressing AMFs were first found in the lung septa 
at PND1, and accumulated in the alveolar lumen at PND3 
(Fig. 2 E). When we studied lungs before birth, the develop­
ing airspaces were completely devoid of mononuclear cells 
(Fig. 2 D and E). Therefore, bona fide SiglecFhiCD11chi AMFs 
only appear in the alveolar space during the first days of life.
Fetal MFs, fetal monocytes, preAMFs, and mature AMFs 
appear in consecutive waves during lung development
The kinetic analysis of lung mononuclear cells and AMF on­
tology demonstrated that the phenotype of lung mononuclear 
cells was highly dynamic, and composed of cells resembling 
fetal monocytes, fetal MFs, and immature AMFs, with signifi­
cant overlap in expression of marker sets. We therefore studied 
the phenotype of mononuclear cells in greater detail, again 
using the basic mononuclear gate and three populations 
CD11chiSiglecFhi, CD11cintSiglecFlo, and CD11cloSiglecFlo as 
the starting gate, just like in adult mice (Fig. 3 A). As illus­
trated in Fig. 3 B for the E17 time point, most mononuclear 
cells were SiglecFloCD11clo cells that could be readily subdivided 
into CD11bintF4/80hi and CD11bhiF4/80int cells. These cells also 
differentially expressed the monocytic marker Ly­6C (Fig. 3 B). 
Ly­6Clo F4/80hi cells highly expressed CD64 (Fig. 3 C), a core 
MF marker (Gautier et al., 2012b; Tamoutounour et al., 2012), 
showed a typical MF morphology on SEM (Fig. 3 D), and 
adhered to plastic in vitro. On the contrary, Ly­6ChiF4/80int did 
not express CD64 and had the typical monocytic FSCloSSClo 
profile (not depicted) and displayed a nonadherent monocytic 
morphology on scanning electron microscopy (SEM; Fig. 3 D), 
thus constituting fetal monocytes. Given their kinetic appear­
ance and resemblance to fetal liver monocytes (not depicted), 
these were likely derived from the liver, the major hematopoietic 
organ at this time period of development. From E18 onwards, 
but culminating around DOB (Fig. 3, A–C, second column), a 
predominant population of SiglecFloCD11cint cells appeared. 
These cells were mainly CD11bhiF4/80int and were Ly­6Cint 
and expressed intermediate levels of CD64. On SEM, these 
cells were larger and more granular like AMFs, but did not 
adhere well to plastic (Fig. 3 D, preAMF). Very few MHCII+ 
DCs were found in this gate (data not shown). At DOB, the 
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has been linked to nonfunctional GM­CSF signaling in patients 
(Suzuki et al., 2008) and could be reproduced in genetically 
modified mice lacking GM­CSF (Csf2/) or GM­CSF­R 
(Csf2r/) expression (Huffman et al., 1996; Reed et al., 1999; 
Reed et al., 2000; Zsengellér et al., 1998). Although the PAP 
syndrome was originally proposed to derive from the fact that 
AMFs were not functional in these mice (REFs; Golde, 1976, 
cells among mature AMFs only dropped very slowly during 
adult life (Fig. 4 D), suggesting that transferred monocytes 
gave rise to a stable self­maintaining population.
GM-CSF drives the development of preAMFs around birth
Primary pulmonary alveolar proteinosis (PAP) is a disease as­
sociated with the accumulation of surfactant in the lungs that 
Figure 3. Fetal MFs, fetal monocytes, 
preAMFs, and mature AMFs appear in 
consecutive waves during lung develop-
ment. Lungs were harvested at various time 
points before and after (PND3, PND14) the 
date of birth (DOB). CD11b+F4/80+ myeloid 
cells were subdivided into CD11cloSigle-Flo, 
CD11cintSigle-Flo, and CD11chiSiglecFhi cells  
(A) and analyzed for Ly-6C, F4/80 (B), and 
CD64 expression (C). (D) Fetal monocytes 
(isolated at E17), fetal MFs (isolated at E17), 
preAMFs (isolated at the DOB), and mature 
AMFs (isolated from adult mice) were sorted, 
put in culture in vitro overnight in complete 
medium, and subjected to electromagnetic 
microscopy to assess their capacity to adhere 
to cell culture plastic and general morphol-
ogy. (E) Percentage of fetal MFs, fetal mono-
cytes, preAMFs, and mature AMFs among 
CD45+ cells in the lungs at the indicated time 
points. Data in A–E represent at least two 
independent experiments involving at least 
three independent mice per time point.
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we decided to investigate the development of AMFs in Csf2/ 
mice. On their DOB, Csf2/ mice completely lacked preAMFs 
(Fig. 5 C). However, they contained fetal MFs and monocytes in 
ratios similar to WT mice (see Fig. 3 for comparison). Note that 
the small CD11cint population that was found in Csf2/ mice 
on DOB was Ly­6Cint, but had a SiglecFloCD64loFSCloSSClo 
profile. Therefore, the wave of preAMFs that is found in WT 
mice around birth is absent in Csf2/ mice. Importantly, de­
velopment of preAMFs or mature AMFs remained absent in 
Csf2/mice throughout life (Fig. 5 E). Liver and splenic 
CD11bintF4/80hi­resident MFs, however, could be readily 
identified in Csf2/ mice (Fig. 5, F and G). In contrast, we 
1979; Harris, 1979; Gonzalez­Rothi and Harris, 1986; Nugent 
and Pesanti, 1983; LeVine et al., 1999; Yoshida et al., 2001; Paine 
et al., 2001; Thomassen et al., 2007), Shibata et al. (2001) later 
proposed that a MF developmental defect rather than a func­
tional defect may lie at the basis of the disease. However, it is 
not known how absence of GM­CSF signaling impacts on 
AMF ontogeny before and shortly after birth. We found that 
lung epithelial cells show an increased expression of GM­CSF 
mRNA that is paralleled by high GM­CSF protein levels in 
lung tissues around DOB, yet quickly wanes thereafter (Fig. 5, 
A and B). Because fetal MFs, fetal monocytes, preAMFs, and 
mature AMFs all express the GM­CSF­R (CD116, Fig. 5 D), 
Figure 4. Fetal monocytes give rise to 
self-maintaining AMFs through a preAMF 
intermediate step. (A and B) CD45.1+ or 
CD45.2+ E17 embryos were sacrificed and 
fetal monocytes and fetal MFs were FACS 
sorted and mixed together at a 50:50 ratio  
(A; left, CD45.1+ fetal monocytes and CD45.2+ 
fetal MFs; right, CD45.1+ fetal MFs and 
CD45.2+ fetal monocytes) and transferred into 
CD45.1+CD45.2+ mice on their DOB. 7 d after 
transfer, CD45.1+CD45.2+ recipient mice were 
sacrificed and the presence of CD45.1+ or 
CD45.2+ donor-derived AMFs was evaluated. 
(B) Summary of data from four independent 
recipient mice. (C) CD45.1+ E17 embryos were 
sacrificed, and fetal monocytes were FACS 
sorted and transferred into CD45.2+ mice on 
their DOB. At the indicated time points after 
transfer, the expression of CD11c, CD11b,  
Ly-6C, SiglecF, and F4/80 was evaluated in 
CD45.1+ fetal monocyte–derived cells. (D) The 
percentage of CD45.1+ fetal monocyte– 
derived cells among mature AMFs at the  
indicated time points after transfer. Data 
represent at least two (A– D) independent 
experiments, with at least three recipient mice 
per time point.
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others have described AMFs with functional defects in adult 
Csf2/ mice. To characterize these cells, we first performed a 
Percoll gradient to remove debris and dead cells form the BAL 
fluid and then used a more general MF gating strategy using 
F4/80 and CD64 (Fig. 5 H). In doing so, we could indeed 
had great difficulty identifying MFs in the BAL of Csf2/ 
mice. Proteinosis had already developed by 4 wk of age and 
yielded autofluorescent debris in the BAL fluid. The presence 
of many dead cells (unpublished data) also rendered the analy­
sis of the cellular composition of the BAL difficult. However, 
Figure 5. Csf2/ mice lack preAMFs and mature AMFs throughout life. (A) Lung epithelial cells isolated at the indicated time points before and 
after birth were FACS sorted, and expression of GM-CSF mRNA was measured by RT-PCR. The expression levels were normalized by comparison with  
expression of the HPRT housekeeping gene. (B) GM-CSF levels in lung homogenates was measured by ELISA at the indicated time points before and after 
birth. (C) Csf2/ mice were sacrificed on their DOB. Lungs were homogenized and CD11b+F4/80+ myeloid cells (gated as indicated) were assessed for  
Ly-6C, CD64, CD11c, F4/80, and SiglecF expression. (D) GM-CSF-R (CD116) expression was evaluated on fetal MFs, fetal monocytes, preAMFs, and mature 
AMFs on the days mentioned using the gating strategy depicted in Fig. 3. (E) The presence of CD11c+SiglecF+ AMFs was evaluated in the BAL of WT and 
Csf2/ mice at the indicated time points after birth. (F and G) The presence of F4/80hiCD11blo splenic MFs and liver MFs (Kupffer Cells) was evaluated in 
adult WT and Csf2/ mice. (H and I) BAL cells from adult WT and Csf2/ mice were subjected to a Percoll gradient to remove dead cells and protein 
debris. The resulting CD64+F4/80+ MFs were assessed for Ly-6C, CD11b, CD11c, and SiglecF expression (I). Data represent two (H and I) and three (A–G) 
independent experiments.
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rGM­CSF treatment (Fig. 6 C), but were unable to significantly 
inhibit the development of PAP, as measured by the amount of 
protein content in the BAL fluid, suggesting that they were not 
only phenotypically but also functionally immature (Fig. 6 D). 
To verify whether these rGM­CSF–rescued immature AMFs 
were irreversibly blocked in the immature AMF stage or 
whether these cells merely lacked the proper cellular environ­
ment to differentiate into mature AMFs we designed a trans­
fer experiment in which immature CD11chiSiglecFintCD11bhi 
AMFs from cytokine­treated CD45.2 Csf2/ mice were 
transferred into a neonatal WT CD45.1 GM­CSF replete hosts 
(Fig. 7). The phenotype of transferred cells was evaluated 2, 9, 
and 42 d after transfer. As shown in Fig. 7, immature AMFs 
gradually further increased expression of CD11c, SiglecF, 
F4/80, and CD64 expression and, as a final step in their mat­
uration process, down­regulated CD11b expression until they 
were undistinguishable from mature AMFs.
DISCUSSION
It is a long­held belief that all MFs develop from circulat­
ing monocytes and constitute a unified MPS, but MFs have 
identify some rare F4/80+CD64+ cells in the BAL of Csf2/ 
mice. These cells did not express a bona fide AMF profile, but 
were found to be SiglecFloCD11bhiCD11cintLy­6Chi­to­int. 
Moreover we could only identify such cells after 4 wk of age, 
i.e., once the first signs of PAP developed.
Perinatal GM-CSF cytokine therapy restores the generation 
of self-maintaining preAMFs in Csf2/ mice
Given the surge of GM­CSF expression in the perinatal period, 
and given the fact that AMFs can self­maintain throughout 
life once generated, we reasoned that perinatal recombinant 
GM­CSF treatment of Csf2/ mice during the first days of life 
might be sufficient to rescue arrested AMF development. Treat­
ment of neonatal Csf2/ mice through local i.n. administra­
tion of rGM­CSF on 1, 3, or 5 consecutive days, lead to the dose­ 
dependent development of cells with a CD11cintSiglecFint­hi 
that resembled AMFs, but had lower expression of SiglecF, and 
had not yet down­regulated CD11b and up­regulated F4/80 
as bona fide mature AMFs (Fig. 6, B and C). Such rescued 
Csf2/ AMFs could self­maintain for several weeks after the 
Figure 6. Perinatal GM-CSF treatment of 
Csf2/ mice restores the generation of self-
maintaining preAMFs. (A and B) Csf2/ mice 
were treated 1 time (1x) on the first day after 
birth, 3 times (3x) on the first 3 d after birth, or  
5 times (5x) on the first 5 d of birth with rGM-CSF 
or PBS i.n. (1 rGM-CSF or PBS treatment per day). 
rGM-CSF–treated or PBS-treated Csf2/ mice 
were sacrificed on PND 7. (A) Lungs were homog-
enized and CD11b+F4/80+ myeloid cells were 
assessed for CD11c and SiglecF expression.  
(B) Expression of FSC, SSC, Ly-6C, CD64, CD11c, 
F4/80, and SiglecF on SiglecFloCD11cloCD11bhiLy-6Chi 
monocytes and SiglecFintCD11chiCD11bhiLy-6Chi 
immature AMFs harvested from Csf2/ mice 
treated for 5 consecutive days with rGM-CSF. 
(C) 5 wk after 5 consecutive rGM-CSF treat-
ments, Csf2/ mice were sacrificed and the 
presence of CD11c+SiglecF+ cells in the BAL was 
evaluated. (D) WT or Csf2/ mice treated with  
5 consecutive treatments of rGM-CSF or PBS 
were sacrificed at 7 wk of age, and the develop-
ment of alveolar proteinosis was evaluated by 
measuring the protein concentration in the BAL. 
Data represent two (D) and three (A– C) indepen-
dent experiments, with at least three recipient 
mice per time point.
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the microglia model and originate from yolk sac MFs (Gomez 
Perdiguero et al., 2013).
Here, using radiation chimeric mice, parabiosis, and adop­
tive cellular transfer models, we investigated the ontogeny of 
AMFs. Confirming the CX3CR1­monocyte fate­mapping 
studies in adult mice (Yona et al., 2013), we demonstrate that 
circulating BM­derived monocytes contribute only minimally 
to the pool of AMFs, except when mice are lethally irradiated, 
emptying the AMF niche. We therefore conclude that there 
must be a self­maintaining, proliferating pool of MFs in the 
lung. During the completion of this manuscript, another group 
reported similar conclusions, showing that this pool of self­
maintaining lung MFs can even fill up the AMF niche after 
AMF depletion caused by influenza infection or DT­mediated 
depletion (Hashimoto et al., 2013).
The fact that adult circulating monocytes only mini­
mally feed the steady­state AMF pool suggested an embryonic 
recently been shown to develop from primitive precursors 
before birth (Geissmann et al., 2010). Both pathways of devel­
opment might be mutually exclusive or coexist. Indeed, micro­
glia originate directly from yolk sac MFs that colonize the 
brain before birth, and then self­maintain throughout life 
without any input from BM­derived precursors (Ajami et al., 
2007; Ginhoux et al., 2010). However, we and others have 
shown that intestinal MFs derive directly from BM­derived 
monocytes that continuously seed the lamina propria and 
differentiate locally into MFs (Bogunovic et al., 2009; Varol 
et al., 2009; Tamoutounour et al., 2012). The specific cellular 
origin of other tissue­resident MFs remains unknown, but 
elegant fate­mapping experiments have demonstrated that 
BM­derived precursors contribute minimally to the pool of 
most tissue­resident MFs across tissues (Schulz et al., 2012; 
Yona et al., 2013). Based on analogy with microglia, it was 
proposed therefore that most tissue­resident MFs may follow 
Figure . Terminal differentiation of GM-CSF–rescued immature AMFs requires a GM-CSF–replete host. Csf2/ mice treated with 5 consecu-
tive treatments of rGM-CSF were sacrificed at 7 d of age. The lungs were homogenized and CD45.2+ CD11cintSiglecFint preAMFs were FACS sorted (profile 
of the sorted cells before transfer is shown in A) and transferred into CD45.1+ WT mice on their DOB. 2 d, 9 d, and 6 wk after transfer, CD45.1+ recipient 
mice were sacrificed, and the presence of CD45.2+ donor-derived cells was evaluated in the lungs (B–D) and BAL (E). Their CD11b, F4/80, CD11c, and  
SiglecF expression profile was also assessed. Data represent two independent experiments with at least three recipient mice per time point.
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and partly from Myb­independent primitive precursors, al­
though it was hard to conclude from the gating strategy 
whether AMFs were included in the analysis, and whether 
other myeloid populations expressing F4/80 such as eosino­
phils were excluded from analysis (Schulz et al., 2012). This 
group also showed that in Myb­deficient embryos, which lack 
fetal monocyte development, an F4/80hi MF population was 
present in the fetal lung. However, as these Myb­deficient em­
bryos never reach term and die from severe anemia at E16.5, 
it is not possible to assess whether these F4/80hi MFs would 
indeed become AMFs, as AMFs only appear after birth. 
Moreover, the F4/80hi cells identified in the lungs of the 
Myb­deficient embryos around E16 are most likely the primi­
tive yolk sac MFs that we also see peaking around this time 
point in WT mice (Fig. 3).
It is remarkable that fetal MFs and monocytes were de­
scribed by Ginhoux et al. (2010) to colonize the developing 
skin at the same time points as we recovered them in the de­
veloping lung, with fetal monocytes giving rise to a special­
ized subset of dendritic cells called LCs (Hoeffel et al., 2012). 
In fact, AMFs and LCs share several unique features: (a) they 
populate a cellular niche where they constitute the only antigen­
presenting cell in the steady state (the alveoli and the epider­
mis, respectively); (b) the alveolar and the epidermal niche are 
not easily accessible to hematopoietic precursors as these are 
barriers to the outside world, probably requiring the LCs and 
AMFs to self­maintain in the steady state; (c) AMFs (this 
study) and LCs (Chorro et al., 2009; Hoeffel et al., 2012) col­
onize their niches in a single wave during the first week after 
birth; and (d) fate­mapping studies demonstrate that AMFs 
(Ginhoux et al., 2010) and LCs (Hoeffel et al., 2012) do not 
derive from yolk sac MFs, but instead derive primarily from 
fetal monocytes (this study; Hoeffel et al., 2012).
The environmental cues that drive AMF and LC differen­
tiation, however, seem to differ significantly. LCs require 
IL­34, but not M­CSF or GM­CSF (Greter et al., 2012a; Greter 
et al., 2012b; Wang et al., 2012), whereas AMFs require GM­
CSF and M­CSF, but not IL­34 for their development (this 
study; Wang et al., 2012; Hashimoto et al., 2013). Around the 
perinatal period, we noticed high expression of GM­CSF 
mRNA in epithelial cells and protein in BAL fluid, but this 
waned rapidly after birth. Analysis of Csf2/ mice demon­
strated that lungs were completely devoid of AMFs, identify­
ing GM­CSF as the driving cytokine for AMF development 
in the perinatal period. Previous work on Csf2/ or Csf2r/ 
mice with pulmonary alveolar proteinosis (PAP) reached con­
flicting results stating that AMF function was impaired (Golde, 
1976, 1979; Harris, 1979; Nugent and Pesanti, 1983; Gonzalez­
Rothi and Harris, 1986; LeVine et al., 1999; Yoshida et al., 
2001; Paine et al., 2001; Thomassen et al., 2007), or that AMF 
development was abnormal (Shibata et al., 2001). Here, we 
show that AMF development is blocked before the preAMF 
stage, and the few MFs that are found in Csf2/ mice are 
most likely inflammatory MFs that accumulate in response to 
lung damage inflicted by surfactant accumulation. Given the 
boost of GM­CSF expression in the perinatal period, and 
precursor, and decided to take a closer look at the nature of 
this embryonic precursor. In our developmental analysis, we did 
not solely rely on expression of the pan MF markers CD64, 
F4/80, and CD11b, but also took advantage of the unique 
and discriminating surface characteristics of mature AMFs 
that express high levels of SiglecF and CD11c. A clearly de­
fined phenotype of the mature tissue­resident MF, allowed us 
to also look for intermediate steps in AMF development, a 
task almost impossible for other tissue­resident MFs for which 
such late maturation markers are often lacking. The early de­
veloping lung (E12, before fetal liver hematopoiesis has 
started) contained mainly F4/80hi CD11bint Ly­6C CD64hi 
cells that had a phenotype and ultrastructure like primitive 
MFs and did not express AMF markers. From E14 onwards, 
we also observed a steady increase in fetal monocytes in the 
developing lung. As definitive hematopoiesis starts only from 
E16.5, these were most likely derived from fetal liver hemato­
poiesis (Costa et al., 2012). Cells with a preAMF phenotype 
started accumulating in the fetal lung around the saccular 
stage of lung development (E18.5), when branching canaliculi 
become narrower and give rise to saccules, which are the pre­
cursors to alveoli (Morrisey and Hogan, 2010). Bona fide ma­
ture SiglecFhiCD11chi AMFs only appeared during the first 
week after birth, and not before birth, as shown for microglia 
(Ginhoux et al., 2010).
As both fetal monocytes and fetal MFs were found in the 
developing lung, the question remained as to which of these 
two were the progenitor to AMFs. Based on kinetic analysis, 
phenotypic changes after adoptive transfer, and competitive 
reconstitution experiments, we concluded that fetal mono­
cytes were the main progenitors to AMFs. First, adoptive 
transfer of E17 fetal monocytes was much more efficient in 
generating long­term engraftment of AMFs compared with 
transfer of E17 fetal MFs. Second, when E17 fetal monocytes 
were transferred and followed over time, they differentiated 
gradually into AMFs, first down­regulating Ly­6C and ac­
quiring CD11c expression, followed by SiglecF acquisition. 
The final step of AMF maturation was accompanied by fur­
ther up­regulation of SiglecF, down­regulation of CD11b and 
up­regulation of F4/80. This entire process took 7 d, which 
would also fit with the kinetics of appearance of the first lung 
fetal monocytes (E14) over an intermediate stage preAMF 
stage around DOB and with the appearance of mature AMFs 
at PND1­3. Third, when adoptively transferred, fetal mono­
cytes gave rise to a long­term population of AMFs that were 
almost not diluted over time. Others have shown, using 
fate mapping experiments, that AMFs do not derive from 
E7 Runx1MER­Cre­MER Rosa­LSL­YFP–tagged yolk sac MFs 
(Ginhoux et al., 2010) or from adult CX3CR1ERCre Rosa­
LSL­YFP–tagged mononuclear cells (Yona et al., 2013), but 
have offered no explanations as to where exactly AMFs do 
derive from. Our study provides direct evidence that fetal 
monocytes are the predominant progenitor to AMFs. One 
group has proposed, using an inducible MxCre­driven Myb 
deficiency abolishing adult hematopoietic cells, a mixed ori­
gin of lung MFs, partly deriving from adult hematopoietic 
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MFs follow the microglia model (yolk sac MF origin), the 
intestinal MF model (BM­monocyte origin), or the AMF/LC 
model (fetal­monocyte origin).
MATERIALS AND METHODS
Mice. C57BL/6 CD45.2+, congenic C57BL/6 CD45.1+ (The Jackson 
Laboratory), Csf2/ and Ccr2/ mice were bred at the animal facility of 
the University of Ghent. For timed pregnancies, female C57B1/6 or GM­CSF 
mice were superovulated with 2 i.u. pregnant mare serum gonadotropin 
(Folligon; Intervet) to stimulate follicle growth and 2 i.u. human chorionic 
gonadotropin (Chorulon; Intervet) to induce ovulation. Mice were housed 
under specific pathogen–free conditions in individually ventilated cages in 
a controlled day–night cycle and given food and water ad libitum. All ex­
periments were approved by the animal ethical committee of the University 
of Ghent.
Generation of BM chimeras and parabiotic mice. C57BL/6 (CD45.1+ 
CD45.2+) mice were lethally irradiated with two doses of 5.5 Gy, and re­
ceived i.v. 2 × 106 BM cells consisting of a 50:50 mix of BM cells obtained 
from femurs and tibias of WT C57BL/6 CD45.1+ and of C57BL/6 Ccr2/ 
CD45.2+ mice. 7 wk after reconstitution, proper blood chimerism was veri­
fied, and mice were analyzed 8 wk after BM transfer.
Parabiotic mice were generated by suturing weight­matched CD45.1+ 
and CD45.2+ mice of 9 wk of age. Parabiotic mice were then kept under 
Bactrim for 2 mo before analysis. As previously described (Liu et al., 2007), 
circulating B cells and T cells equilibrated to almost 50% chimerism at that 
time, indicating efficient exchange between the joined mice.
BrdU labeling in vivo and cell cycle analysis. Mice were injected i.p. 
with 1.5 mg BrdU (Sigma­Aldrich) to ensure its immediate availability, and 
their drinking water was supplemented for up to 28 d with 0.8 mg/ml 
of BrdU and 2% glucose and changed daily. Lung cells were stained first for 
surface markers and then permeabilized for BrdU staining (BrdU labeling 
Flow kit; BD). Ki­67 staining (BD) was performed using the staining proto­
col corresponding to the Foxp3 labeling Flow kit (eBioscience).
Flow cytometry and cell sorting. Flow cytometric studies were per­
formed using a LSRII (BD) with subsequent data analysis using FlowJo soft­
ware (Tree Star). Cell sorting was performed on a FACSAria II cytometer. 
After cell sorting, purity was checked (always >95%). For flow cytometry, 
lungs were cut into small pieces, incubated in RPMI containing Liberase TM 
(Roche) and DNase (Roche), and then syringed through a 19­gauge needle 
to obtain a homogenous cell suspension. Red blood cells were lysed for 
4 min at room temperature in 1 ml osmotic lysis buffer. For flow cytometry 
of BAL derived from GM­CSF mice diagnosed with proteinosis, BAL cells 
were first enriched using a Percoll gradient (Sigma­Aldrich).
Fluorochrome­ or biotin­conjugated mAbs specific for mouse CD11c 
(clone N418), CD3 (clone 145­2C11), CD19 (clone 1D3), Ly­6G (clone 
1A8), CD11b (clone M1/70), CD64 (clone X54­5/7.1), Ly­6C (clone 
AL21), SiglecF (clone E50­2440), SAV, Ki­67 (clone B56), Sca­1 (clone d7), 
CD45.1 (clone A20), and CD45.2 (clone 104); the corresponding isotypes; 
and the secondary reagent PE­Texas red–conjugated streptavidin were all 
purchased from BD or eBioscience. Anti­MHCII (clone M5/114) and anti­
Epcam (clone G8.8) were purchased from BioLegend. Anti­F4/80 (clone 
A3­1) was purchased from Serotec. Neutrophils (Ly­6GhiCD11bhiCD64lo 
Ly­6Chi cells), Eosinophils (SiglecFhiCD11bhiCD64loLy­6Cint cells), T cells 
(CD3hiCD11bloCD64lo cells), and B cells (CD19hiCD11bloCD64lo cells) were 
systematically outgated before analysis. Fixable live/dead marker Aqua was 
purchased from Invitrogen. Dead cells were outgated using the live/marker 
before analysis.
Transfer of sorted cells. Fetal monocytes and fetal MFs were sorted from 
the lungs of time­mated E17 C57BL/6 CD45.2+ and CD45.1+ embryos. 
given the fact that AMFs can self­maintain throughout life 
once generated, we reasoned that perinatal recombinant 
GM­CSF treatment of Csf2/ mice during the first days of 
life might be sufficient to rescue arrested AMF development. 
Perinatal GM­CSF for 5­d treatment, indeed, rescued long­
term CD11chiSiglecFint AMF development, AMFs appeared 
in the alveolar lumen, but these AMFs were in an immature 
state, failing to down­regulate CD11b and to prevent PAP. It 
is possible that 5 d of GM­CSF treatment of Csf2/ mice 
was insufficient to cause full AMF differentiation, or that 
continuous low­level GM­CSF production in a replete host 
induces a second signal permissive to terminal AMF differen­
tiation. In support, adoptive transfer of immature AMFs from 
GM­CSF–treated Csf2/ mice to WT mice allowed the ter­
minal differentiation of immature AMFs, a process that took 
a few days. We can only speculate as to what exactly this sec­
ond signal might be. Previous work identified PPAR as 
a crucial transcription factor for AMF development necessary 
to prevent PAP (Baker et al., 2010; Gautier et al., 2012a). 
GM­CSF induces PPAR gene expression (Bonfield et al., 
2003). However, we administered the PPAR agonist rosigli­
tazone in the perinatal period, and this failed to terminally 
differentiate AMFs in GM­treated Csf2/ mice (unpub­
lished observations). Studies in humanized mice confirm the 
essential role of GM­CSF in human AMF development. 
Mouse GM­CSF does not bind to human GM­CSF­R, and 
therefore these humanized mice do not possess human AMFs. 
Mice in which the mouse Csf2 locus was replaced by the 
human coding sequence lacked murine AMFs (Willinger 
et al., 2011), and without engraftment of human HSCs they 
developed PAP. After human HSC engraftment, MFs of 
human origin were found in the BAL, but these MFs were 
incapable of fully protecting against PAP. This suggests that, in 
humans as well as in mice, GM­CSF alone may not be suffi­
cient to generate fully functional and terminally differenti­
ated AMFs. Strikingly, a recent paper also identified GM­CSF 
as the cytokine necessary for the proliferation and self­
maintenance of AMFs after local depletion from the lungs 
(Hashimoto et al., 2013).
In conclusion, we have elucidated the pathway of AMF 
development by showing that fetal monocytes develop into 
preAMFs around the time that airspaces (fluid filled sac­
culi) start to occur during lung development. At the DOB, 
most preAMFs are still in the alveolar septa, but shortly 
thereafter they end up in the alveolar space as immature 
AMFs, and then rapidly down­regulate CD11b and be­
come functionally mature cells that self­maintain and do 
not require input from circulating hematopoietic precur­
sors. Importantly, the appearance of such preAMFs seems to 
be restricted to a single wave around birth and accompa­
nied by a boost of GM­CSF around this period, which is 
necessary for proper AMF instruction. In the broader con­
text of MF development, we provide evidence for a third 
model for the origin of tissue­resident MF, whereby AMFs 
originate from fetal monocytes during the perinatal period. 
It remains to be investigated whether other tissue­resident 
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